Febrile neutropenia-related care and associated costs in elderly patients with breast cancer, lung cancer, or non-Hodgkin lymphoma
Limited information is available regarding elderly patients experiencing febrile neutropenia (FN). This study evaluated FN-related care among elderly cancer patients who received high/intermediate FN-risk chemotherapy and experienced ≥ 1 FN episodes.
We used Medicare data to identify patients aged ≥ 66 years who initiated high/intermediate FN-risk chemotherapy between 1 January 2008 and 31 August 2015 to treat breast cancer (BC), lung cancer (LC), or non-Hodgkin lymphoma (NHL) and had ≥ 1 FN episodes. We identified within-cycle FN episodes for each chemotherapy cycle on Part A inpatient claims or outpatient or Part B claims. We described the FN-related care setting (inpatient hospital, outpatient emergency department [ED], or outpatient non-ED) and reported mean total cost of FN-related care per episode overall and by care setting (adjusted to 2015 US$).
We identified 2138, 3521, and 2862 patients with BC, LC, and NHL, respectively, with ≥ 1 FN episodes (total episodes: 2407, 3840, 3587, respectively). Most FN episodes required inpatient care (BC, 88.1%; LC, 93.0%; NHL, 93.2%) with mean hospital length of stay (LOS) 6.2, 6.5, and 6.8 days, respectively. Intensive care unit admission was required for 20.4% of BC, 29.0% of LC, and 25.7% of NHL hospitalizations (mean LOS: 4.7, 4.7, 5.5 days, respectively). The mean total cost of FN care per episode was $11,959 BC, $14,388 LC, and $15,006 NHL, with inpatient admission the costliest care component ($11,826; $14,294; and $14,873; respectively).
Among elderly patients with BC, LC, or NHL who experienced FN, most FN episodes required costly hospital care, highlighting the FN burden on healthcare systems.
KeywordsChemotherapy Elderly patients Febrile neutropenia Healthcare costs Medicare
Medical writing support was provided by Martha Mutomba (on behalf of Amgen Inc.) and Micah Robinson (of Amgen Inc.). The authors thank Chronic Disease Research Group colleague Nan Booth for manuscript editing.
This study was supported by Amgen, Inc.
Compliance with ethical standards
Conflict of interest
Shuling Li and Jiannong Liu are employees of Chronic Disease Research Group, Hennepin Healthcare Research Institute, which has received project funding from Amgen, Inc. Charles Bowers, Tamer A. F. S. Garawin, Christopher Kim, Mark E. Bensink, and David B. Chandler are employees of and own stock in Amgen, Inc.
Research involving human participants and/or animals
This article does not contain any studies with human participants or animals performed by any of the authors.
Formal consent was not required as the article does not contain any studies involving human participants performed by any of the authors.
- 14.United States Department of Labor Website. CPI Inflation Calculator. Bureau of Labor Statistics. Available at: https://www.bls.gov/data/inflation_calculator.htm. Accessed 22 Feb 2019
- 15.National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines®). Myeloid growth factors. V1.2018. Available at: http://www.nccn.org/professionals/physician_gls/pdf/myeloid_growth.pdf. Accessed 22 Feb 2019
- 16.Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, Lyman GH, Pettengell R, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C, EOfR, Cancer To (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47:8–32CrossRefGoogle Scholar
- 19.National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines®). Older adult oncology. Version 1.2018. Available at: http://www.nccn.org/professionals/physician_gls/pdf/senior.pdf. Accessed 22 Feb 2019
- 20.Morrison VA, Picozzi V, Scott S, Pohlman B, Dickman E, Lee M, Lawless G, Kerr R, Caggiano V, Delgado D, Fridman M, Ford J, Carter WB, Group OPPSW (2001) The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin’s lymphoma receiving initial CHOP chemotherapy: a risk factor analysis. Clin Lymphoma 2:47–56CrossRefGoogle Scholar
- 26.National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines®). Myeloid growth factors. 2015. Available at: http://www.nccn.org/professionals/physician_gls/pdf/myeloid_growth.pdf. Accessed 22 Feb 2019
- 30.Centers for Medicare & Medicaid Services. CMS.gov. Market Basket Data. Actual regulation market basket change and Medicare payment updates as published in the “Federal Register”. Available at: http://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/MedicareProgramRatesStats/MarketBasketData.html. Accessed 22 Feb 2019